MIST Milestone Pharmaceuticals Inc

Price (delayed)

$1.29

Market cap

$160.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$226.61M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 21

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada ...

Highlights
MIST's quick ratio has soared by 104% YoY and by 15% from the previous quarter
Milestone Pharmaceuticals's revenue has increased by 15% QoQ
MIST's debt has soared by 147% YoY and by 135% QoQ
The net income fell by 32% YoY and by 8% QoQ

Key stats

What are the main financial stats of MIST

MIST stock price

How has the Milestone Pharmaceuticals stock price performed over time
Intraday
0.78%
1 week
-10.42%
1 month
-31.93%
1 year
-21.82%
YTD
-36.14%
QTD
8.4%

Financial performance

How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$1.78M
Gross profit
$1.77M
Operating income
-$65.28M
Net income
-$68.36M
Gross margin
99.2%
Net margin
-3,832%
The net income fell by 32% YoY and by 8% QoQ
The operating income has contracted by 25% YoY and by 5% from the previous quarter
Milestone Pharmaceuticals's revenue has increased by 15% QoQ
The gross profit is up by 14% since the previous quarter

Price vs fundamentals

How does MIST's price correlate with its fundamentals

Growth

What is Milestone Pharmaceuticals's growth rate over time

Valuation

What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.21
P/S
94.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
127.03
The EPS is up by 14% YoY and by 11% QoQ
The P/B is 27% higher than the 5-year quarterly average of 3.3
The company's equity fell by 14% QoQ
Milestone Pharmaceuticals's revenue has increased by 15% QoQ

Efficiency

How efficient is Milestone Pharmaceuticals business performance
Milestone Pharmaceuticals's return on equity has increased by 48% QoQ but it has decreased by 3% YoY
The ROIC has increased by 37% QoQ but it has decreased by 10% YoY
MIST's ROA is up by 24% QoQ and by 8% YoY
The ROS is up by 10% QoQ

Dividends

What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIST.

Financial health

How did Milestone Pharmaceuticals financials performed over time
The total assets is 23% greater than the total liabilities
Milestone Pharmaceuticals's total liabilities has soared by 132% YoY and by 120% from the previous quarter
MIST's quick ratio has soared by 104% YoY and by 15% from the previous quarter
MIST's debt to equity has surged by 172% since the previous quarter and by 142% year-on-year
MIST's debt has soared by 147% YoY and by 135% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.